Drug compounders are entering uncertain regulatory territory as the FDA reevaluates restrictions on peptides, which have become popular due to wellness influencers. The FDA’s advisory committee on pharmacy compounding plans to meet in July to discuss the potential inclusion of peptides in the 503A bulk list, which would permit their legal customization. Peptides, essential for protein and signaling molecule formation in the body, are under investigation for various health applications.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://news.bloomberglaw.com/pharma-and-life-sciences/fdas-fresh-look-at-peptides-leaves-drug-compounders-in-limbo
